Mankind Pharma's Board of Directors has approved incorporation of a wholly owned subsidiary in the Netherlands to support investments in research and development assets and business development for niche therapies 

The Company’s board also gave its nod for the divestment of its wholly owned subsidiary Broadway Hospitality Services Pvt. Ltd. and

The decisions were approved at the company's board meeting held on July 11 and disclosed in a regulatory filing.

As part of its strategy to monetise non-core assets, Mankind Pharma will sell its entire 100% stake in Broadway Hospitality Services to AKRK Projects LLP and Partners for a consideration of Rs. 49 crore, subject to customary closing adjustments. 

The transaction is expected to be completed within 90 days.

Broadway Hospitality contributed Rs. 9.63 crore in revenue and had a net worth of Rs. 38.99 crore during FY26, accounting for just 0.07% of the company's revenue and 0.24% of its net worth, according to the filing. 

The company clarified that the buyers are not part of the promoter or promoter group, and the transaction does not constitute a related-party transaction.

In a separate strategic move, the board approved the incorporation of a wholly owned subsidiary (WOS) in the Netherlands, which will serve as a special purpose vehicle for holding investments in R&D assets and pursuing business development activities focused on niche therapies.

The proposed subsidiary will evaluate opportunities through joint ventures and strategic investments in innovative therapeutic areas. Mankind Pharma plans to invest up to €5 million, in one or more tranches, towards the subsidiary's equity capital and operational requirements. 

The investment will be made in compliance with the applicable provisions of the Foreign Exchange Management Act (FEMA), Reserve Bank of India regulations and regulatory requirements in the Netherlands.

The twin decisions reflect Mankind Pharma's strategy of streamlining its portfolio by exiting non-core businesses while strengthening its global innovation footprint through dedicated investments in research-led and specialty pharmaceutical opportunities.